FDA clears Takeda’s Entyvio injection for Crohn’s disease

19 Apr 2024
firstwordpharma.com
Phase 3Drug ApprovalClinical Result
The subcutaneous (SC) version of Takeda’s Entyvio (vedolizumab) scored its second US win on Thursday when the FDA approved the gut-selective α4β7 integrin inhibitorα4β7 integrin inhibitor as maintenance therapy for Crohn’s disease. The regulator gave the injectable a green light for ulcerative colitis (UC) last September.
The approval for SC Entyvio, which can now be given to adults with moderately to severely active Crohn’s disease after induction therapy with an intravenous (IV) formulation, is based on results of the Phase III VISIBLE 2 trial. The study randomised 409 patients to receive either the biologic or placebo every two weeks, following induction. About 48% of patients with Crohn’s disease who received SC Entyvio were in clinical remission at week 52 compared with 34% for the placebo arm, achieving statistical significance.
The label expansion might help improve sales of the single-dose prefilled pen, which have been hampered by insurer pushback due to its high cost. However, a key opinion leader told FirstWord in February that in a year’s time, there is “a good chance” half of the IV Entyvio patients with UC will be on the SC formulation. For more, see KOL Views Q&A: Takeda's SC Entyvio sees slower than expected uptake in UC.
The EU cleared SC Entyvio for Crohn’s disease and UC in 2020.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.